Tech & Science Daily podcast: Alzheimer’s disease drug breakthrough

Plus, YouTuber & daredevil Danny MacAskill
AP
Rachelle Abbott30 November 2022

An Alzheimer’s drug could mean the ‘beginning of the end’ for the disease.

Dr Bart De Strooper, Director of the UK Dementia Research Institute, explains why the results from the Lecanemab trial are so groundbreaking and what this means moving forward.

It’s the first treatment to slow the destruction of the brain and clear clumps of a protein from patients’ brains which is thought to be a key cause of the most common form of dementia.

YouTuber and daredevil Danny MacAskill tells Tech & Science Daily why he’s going old school with his videos.

He’s just finished his latest project filming stunts around San Francisco - something he started in 2017 - but had to put on the backburner, after breaking his kneecap on day two of filming.

A study suggests that bats have a greater vocal range than singers like Mariah Carey.

They can produce a range of frequencies that far exceeds vertebrates including humans - and even a certain queen of Christmas.

And the rest

Tesla is 'redesigning’ the Model 3 to cut costs as stock slumps 20%, researchers discover two new minerals on a meteorite in Somalia and China sends a new crew to the Tiangong space station.

Plus, a creepy deepfake of Meta CEO Mark Zuckerberg goes viral and an update on Christmas turkey supplies…

Listen here or here:

You can find us on your Spotify Daily Drive or wherever you stream your podcasts.

Create a FREE account to continue reading

eros

Registration is a free and easy way to support our journalism.

Join our community where you can: comment on stories; sign up to newsletters; enter competitions and access content on our app.

Your email address

Must be at least 6 characters, include an upper and lower case character and a number

You must be at least 18 years old to create an account

* Required fields

Already have an account? SIGN IN

By clicking Create Account you confirm that your data has been entered correctly and you have read and agree to our Terms of use , Cookie policy and Privacy policy .

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged in